Thijs Luc Junior van Osch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thijs Luc Junior van Osch has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Gestur Vidarsson
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
8 shared publications Jan Nouta
6 shared publications- Manfred Wuhrer
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
6 shared publications - C. Ellen van der Schoot
Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
4 shared publications Remco Visser
4 shared publications- Tamas Pongracz
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
4 shared publications
Latest Publications
- Open Access
- 5 August 2025
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 52 (5) , 1-14
IgG-Fc Glycosylation and a Novel Flowcytometric Assay to Predict Hemolytic Disease of the Fetus and Newborn
Introduction: Timely and accurate referral of pregnancies with red blood cell alloantibodies is essential to prevent perinatal death or long-term adverse consequences in hemolytic disease of the fetus and newborn (HDFN). Classically, antibody titers are used to select high-risk pregnancies. Research suggested that also IgG-Fc fucosylation could be an important pathological feature. We evaluated the diagnostic potential of IgG-Fc fucosylation in identifying high-risk pregnancies, and we report on a flowcytometric assay that integrates antibody quantity, antibody subclass and fetal FcγRIIIa affinity. Methods: Maternal serum samples from a nationwide prospective cohort of D-alloimmunized pregnancies, between 2014 and 2017, were used to evaluate IgG-Fc glycosylation in mass spectrometry (n = 64) and the flowcytometric assay (n = 90). Results were compared to standard-of-care titers and antibody-dependent cellular cytotoxicity (ADCC) assay results. Receiver operating characteristic (ROC) curves were used to assess and quantify predictive values. Results: The cohort for mass-spectrometry analysis consisted of 31 pregnancies without transfusions (48%), 16 with intrauterine transfusion (IUT) (25%), and 17 (27%) with postnatal transfusions only. The flowcytometric assay consisted of 53 (59%) pregnancies without transfusions, 17 (19%) pregnancies with IUT, and 20 (22%) pregnancies with postnatal transfusions only, suggesting that severe HDFN was overrepresented. Anti-D IgG1 and IgG3-Fc-fucosylation levels were lower in groups requiring transfusions, but no distinct difference between groups was detected. No significant difference in other glycan traits was found. Among sera from 90 D-alloimmunized pregnancies evaluated in the flowcytometric assay, we found significant differences in IgG and FcγRIIIa bindings between pregnancies without transfusions and with IUT, suggesting a potential predictive value for the need for IUTs. ROC analyses revealed a lower false-positive rate at a 100% sensitivity in the prediction of pregnancies at risk for fetal anemia through the flowcytometric assay (20.8% for IgG binding and 43.1% for FcγRIIIa binding) compared to the titer and ADCC (74.6%). Conclusion: Anti-D IgG-Fc-fucosylation levels tended to be lower in pregnancies with IUT but could not distinguish pregnancies with or without IUT in this cohort. The flowcytometric assay, measuring IgG levels and functional FcγRIIIa binding, indicates that the specificity of serological monitoring in HDFN may be improved. Considering an overrepresentation of severe HDFN in this cohort, we advise to confirm these findings in a prospective cohort within a routine setting.
- 5 August 2025
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 52 (5) , 1-14
Open AccessIgG-Fc Glycosylation and a Novel Flowcytometric Assay to Predict Hemolytic Disease of the Fetus and Newborn
Introduction: Timely and accurate referral of pregnancies with red blood cell alloantibodies is essential to prevent perinatal death or long-term adverse consequences in hemolytic disease of the fetus and newborn (HDFN). Classically, antibody titers are used to select high-risk pregnancies. Research suggested that also IgG-Fc fucosylation could be an important pathological feature. We evaluated the diagnostic potential of IgG-Fc fucosylation in identifying high-risk pregnancies, and we report on a flowcytometric assay that integrates antibody quantity, antibody subclass and fetal FcγRIIIa affinity. Methods: Maternal serum samples from a nationwide prospective cohort of D-alloimmunized pregnancies, between 2014 and 2017, were used to evaluate IgG-Fc glycosylation in mass spectrometry (n = 64) and the flowcytometric assay (n = 90). Results were compared to standard-of-care titers and antibody-dependent cellular cytotoxicity (ADCC) assay results. Receiver operating characteristic (ROC) curves were used to assess and quantify predictive values. Results: The cohort for mass-spectrometry analysis consisted of 31 pregnancies without transfusions (48%), 16 with intrauterine transfusion (IUT) (25%), and 17 (27%) with postnatal transfusions only. The flowcytometric assay consisted of 53 (59%) pregnancies without transfusions, 17 (19%) pregnancies with IUT, and 20 (22%) pregnancies with postnatal transfusions only, suggesting that severe HDFN was overrepresented. Anti-D IgG1 and IgG3-Fc-fucosylation levels were lower in groups requiring transfusions, but no distinct difference between groups was detected. No significant difference in other glycan traits was found. Among sera from 90 D-alloimmunized pregnancies evaluated in the flowcytometric assay, we found significant differences in IgG and FcγRIIIa bindings between pregnancies without transfusions and with IUT, suggesting a potential predictive value for the need for IUTs. ROC analyses revealed a lower false-positive rate at a 100% sensitivity in the prediction of pregnancies at risk for fetal anemia through the flowcytometric assay (20.8% for IgG binding and 43.1% for FcγRIIIa binding) compared to the titer and ADCC (74.6%). Conclusion: Anti-D IgG-Fc-fucosylation levels tended to be lower in pregnancies with IUT but could not distinguish pregnancies with or without IUT in this cohort. The flowcytometric assay, measuring IgG levels and functional FcγRIIIa binding, indicates that the specificity of serological monitoring in HDFN may be improved. Considering an overrepresentation of severe HDFN in this cohort, we advise to confirm these findings in a prospective cohort within a routine setting.
- Top Cited Papers
- 4 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (1) , 79-91
Complement activation drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs
Transfusion-related acute lung injury (TRALI) is one of the leading causes of transfusion-related fatalities and, to date, is without available therapies. Here, we investigated the role of the complement system in TRALI. Murine anti–major histocompatibility complex class I antibodies were used in TRALI mouse models, in combination with analyses of plasma samples from patients with TRALI. We found that in vitro complement activation was related to in vivo antibody-mediated TRALI induction, which was correlated with increased macrophage trafficking from the lungs to the blood in a fragment crystallizable region (Fc)-dependent manner and that this was dependent on C5. Human immunoglobulin G 1 variants of the murine TRALI-inducing antibody 34-1-2S, either unable to activate complement and/or bind to Fcγ receptors (FcγRs), revealed an essential role for the complement system, but not for FcγRs, in the onset of 34-1-2S–mediated TRALI in mice. In addition, we found high levels of complement activation in the plasma of patients with TRALI (n = 53), which correlated with elevated neutrophil extracellular trap (NET) markers. In vitro we found that NETs could be formed in a murine, 2-hit model, mimicking TRALI with lipopolysaccharide and C5a stimulation. Collectively, this reveals a critical role of Fc-mediated complement activation in TRALI, with a direct relation to macrophage trafficking from the lungs to the blood and an association with NET formation, suggesting that targeting the complement system may be an attractive therapeutic approach for combating TRALI.
- 4 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (1) , 79-91
Top Cited PapersComplement activation drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs
Transfusion-related acute lung injury (TRALI) is one of the leading causes of transfusion-related fatalities and, to date, is without available therapies. Here, we investigated the role of the complement system in TRALI. Murine anti–major histocompatibility complex class I antibodies were used in TRALI mouse models, in combination with analyses of plasma samples from patients with TRALI. We found that in vitro complement activation was related to in vivo antibody-mediated TRALI induction, which was correlated with increased macrophage trafficking from the lungs to the blood in a fragment crystallizable region (Fc)-dependent manner and that this was dependent on C5. Human immunoglobulin G 1 variants of the murine TRALI-inducing antibody 34-1-2S, either unable to activate complement and/or bind to Fcγ receptors (FcγRs), revealed an essential role for the complement system, but not for FcγRs, in the onset of 34-1-2S–mediated TRALI in mice. In addition, we found high levels of complement activation in the plasma of patients with TRALI (n = 53), which correlated with elevated neutrophil extracellular trap (NET) markers. In vitro we found that NETs could be formed in a murine, 2-hit model, mimicking TRALI with lipopolysaccharide and C5a stimulation. Collectively, this reveals a critical role of Fc-mediated complement activation in TRALI, with a direct relation to macrophage trafficking from the lungs to the blood and an association with NET formation, suggesting that targeting the complement system may be an attractive therapeutic approach for combating TRALI.
- Open Access
- 16 December 2022
- Published by Elsevier in EBioMedicine
- Vol. 87, 104408
The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
- 16 December 2022
- Published by Elsevier in EBioMedicine
- Vol. 87, 104408
Open AccessThe BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
- Open Access
- 3 October 2022
- Published by Taylor & Francis in Platelets
- Vol. 34 (1) , 2129604
Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages
Immune-mediated platelet refractoriness (PR) remains a significant problem in the setting of platelet transfusion and is predominantly caused by the presence of alloantibodies directed against class I human leukocyte antigens (HLA). Opsonization of donor platelets with these alloantibodies can result in rapid clearance after transfusion via multiple mechanisms, including antibody dependent cellular phagocytosis (ADCP). Interestingly, not all alloimmunized patients develop PR to unmatched platelet transfusions, suggesting variation in HLA-specific IgG responses between patients. Previously, we observed that the glycosylation profile of anti-HLA antibodies was highly variable between PR patients, especially with respect to Fc galactosylation, sialylation and fucosylation. In the current study, we investigated the effect of different Fc glycosylation patterns, with known effects on complement deposition and FcγR binding, on phagocytosis of opsonized platelets by monocyte-derived human macrophages. We found that the phagocytosis of antibody- and complement-opsonized platelets, by monocyte derived M1 macrophages, was unaffected by these qualitative IgG-glycan differences.
- 3 October 2022
- Published by Taylor & Francis in Platelets
- Vol. 34 (1) , 2129604
Open AccessPhagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages
Immune-mediated platelet refractoriness (PR) remains a significant problem in the setting of platelet transfusion and is predominantly caused by the presence of alloantibodies directed against class I human leukocyte antigens (HLA). Opsonization of donor platelets with these alloantibodies can result in rapid clearance after transfusion via multiple mechanisms, including antibody dependent cellular phagocytosis (ADCP). Interestingly, not all alloimmunized patients develop PR to unmatched platelet transfusions, suggesting variation in HLA-specific IgG responses between patients. Previously, we observed that the glycosylation profile of anti-HLA antibodies was highly variable between PR patients, especially with respect to Fc galactosylation, sialylation and fucosylation. In the current study, we investigated the effect of different Fc glycosylation patterns, with known effects on complement deposition and FcγR binding, on phagocytosis of opsonized platelets by monocyte-derived human macrophages. We found that the phagocytosis of antibody- and complement-opsonized platelets, by monocyte derived M1 macrophages, was unaffected by these qualitative IgG-glycan differences.
- Open Access
- 27 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (12) , 3011-3025
Altered Fc glycosylation of anti‐HLA alloantibodies in hemato‐oncological patients receiving platelet transfusions
- 27 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (12) , 3011-3025
Open AccessAltered Fc glycosylation of anti‐HLA alloantibodies in hemato‐oncological patients receiving platelet transfusions
- Open Access
- 11 August 2022
- Published by Elsevier in SSRN Electronic Journal
The BNT162b2 mRNA SARS-CoV-2 Vaccine Induces Transient Afucosylated IgG1 in Naive But Not in Antigen-Experienced Vaccinees
Background: Afucosylated IgG responses have been found only against membrane-embedded epitopes, including anti-S in SARS-CoV-2 infections. These responses, intrinsically protective through enhanced FcgRIIIa binding, also trigger exacerbated pro-inflammatory responses in severe COVID-19. We investigated if the BNT162b2 SARS-CoV-2 mRNA also induced afucosylated IgG responses. Methods: Blood from vaccinees during the first vaccination wave was collected. MS was used to study anti-S IgG1-Fc glycoprofiling. Responsiveness of alveolar-like macrophages to produce proinflammatory cytokines in presence of sera and antigen was tested. Antigen-specific B cells were characterized and glycosyltransferase levels were investigated by FACS. Findings: Transient afucosylated anti-S IgG1 responses were found in naive vaccinees, but not in antigen-experienced vaccinees. All vaccinees had increased galactosylation and sialylation of anti-S IgG1. Both naive and antigen-experienced vaccinees showed relative low macrophage activation potential as expected due to the low antibody levels for naive individuals with afucosylated IgG, and high fucosylation levels for antigen-experienced individuals with high levels of anti-S. Afucosylation levels correlated with FUT8 expression in antigen-specific plasma cells in naive individuals. Importantly, low fucosylation of anti-S IgG upon seroconversion correlated with high IgG levels after the second dose. Interpretation: Here, for the first time, we show that BNT162b2 mRNA vaccination induces transient afucosylated anti-S IgG1 responses in naive individuals. This observation warrants further studies to elucidate the clinical context in which potent afucosylated responses would be preferred. Funding: LSBR 1721, 1908; ZonMW 10430012010021, 09150161910033; DFG 398859914, 400912066, 390884018; PMI; DOI4-Nr. 3; H2020-MSCA-ITN 721815. Declaration of Interest: The authors declare that they have no conflicts of interest. Ethical Approval: The ethics committee of the AUMC approved the study.
- 11 August 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe BNT162b2 mRNA SARS-CoV-2 Vaccine Induces Transient Afucosylated IgG1 in Naive But Not in Antigen-Experienced Vaccinees
Background: Afucosylated IgG responses have been found only against membrane-embedded epitopes, including anti-S in SARS-CoV-2 infections. These responses, intrinsically protective through enhanced FcgRIIIa binding, also trigger exacerbated pro-inflammatory responses in severe COVID-19. We investigated if the BNT162b2 SARS-CoV-2 mRNA also induced afucosylated IgG responses. Methods: Blood from vaccinees during the first vaccination wave was collected. MS was used to study anti-S IgG1-Fc glycoprofiling. Responsiveness of alveolar-like macrophages to produce proinflammatory cytokines in presence of sera and antigen was tested. Antigen-specific B cells were characterized and glycosyltransferase levels were investigated by FACS. Findings: Transient afucosylated anti-S IgG1 responses were found in naive vaccinees, but not in antigen-experienced vaccinees. All vaccinees had increased galactosylation and sialylation of anti-S IgG1. Both naive and antigen-experienced vaccinees showed relative low macrophage activation potential as expected due to the low antibody levels for naive individuals with afucosylated IgG, and high fucosylation levels for antigen-experienced individuals with high levels of anti-S. Afucosylation levels correlated with FUT8 expression in antigen-specific plasma cells in naive individuals. Importantly, low fucosylation of anti-S IgG upon seroconversion correlated with high IgG levels after the second dose. Interpretation: Here, for the first time, we show that BNT162b2 mRNA vaccination induces transient afucosylated anti-S IgG1 responses in naive individuals. This observation warrants further studies to elucidate the clinical context in which potent afucosylated responses would be preferred. Funding: LSBR 1721, 1908; ZonMW 10430012010021, 09150161910033; DFG 398859914, 400912066, 390884018; PMI; DOI4-Nr. 3; H2020-MSCA-ITN 721815. Declaration of Interest: The authors declare that they have no conflicts of interest. Ethical Approval: The ethics committee of the AUMC approved the study.
- Open Access
The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not antigen-experienced vaccinees
The onset of severe SARS-CoV-2 infection is characterized by the presence of afucosylated IgG1 responses against the viral spike (S) protein, which can trigger exacerbated inflammatory responses. Here, we studied IgG glycosylation after BNT162b2 SARS-CoV-2 mRNA vaccination to explore whether vaccine-induced S protein expression on host cells also generates afucosylated IgG1 responses. SARS-CoV-2 naive individuals initially showed a transient afucosylated anti-S IgG1 response after the first dose, albeit to a lower extent than severely ill COVID-19 patients. In contrast, previously infected, antigen-experienced individuals had low afucosylation levels, which slightly increased after immunization. Afucosylation levels after the first dose correlated with low fucosyltransferase 8 (FUT8) expression levels in a defined plasma cell subset. Remarkably, IgG afucosylation levels after primary vaccination correlated significantly with IgG levels after the second dose. Further studies are needed to assess efficacy, inflammatory potential, and protective capacity of afucosylated IgG responses. One sentence summary A transient afucosylated IgG response to the BNT162b2 mRNA vaccine was observed in naive but not in antigen-experienced individuals, which predicted antibody titers upon the second dose.
Open AccessThe BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not antigen-experienced vaccinees
The onset of severe SARS-CoV-2 infection is characterized by the presence of afucosylated IgG1 responses against the viral spike (S) protein, which can trigger exacerbated inflammatory responses. Here, we studied IgG glycosylation after BNT162b2 SARS-CoV-2 mRNA vaccination to explore whether vaccine-induced S protein expression on host cells also generates afucosylated IgG1 responses. SARS-CoV-2 naive individuals initially showed a transient afucosylated anti-S IgG1 response after the first dose, albeit to a lower extent than severely ill COVID-19 patients. In contrast, previously infected, antigen-experienced individuals had low afucosylation levels, which slightly increased after immunization. Afucosylation levels after the first dose correlated with low fucosyltransferase 8 (FUT8) expression levels in a defined plasma cell subset. Remarkably, IgG afucosylation levels after primary vaccination correlated significantly with IgG levels after the second dose. Further studies are needed to assess efficacy, inflammatory potential, and protective capacity of afucosylated IgG responses. One sentence summary A transient afucosylated IgG response to the BNT162b2 mRNA vaccine was observed in naive but not in antigen-experienced individuals, which predicted antibody titers upon the second dose.
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1545-1554
Fc Galactosylation Promotes Hexamerization of Human IgG1, Leading to Enhanced Classical Complement Activation
Human IgG contains one evolutionarily conserved N-linked glycan in its Fc region at position 297. This glycan is crucial for Fc-mediated functions, including its induction of the classical complement cascade. This is induced after target recognition through the IgG–Fab regions, allowing neighboring IgG–Fc tails to associate through Fc:Fc interaction, ultimately leading to hexamer formation. This hexamerization seems crucial for IgG to enable efficient interaction with the globular heads of the first complement component C1q and subsequent complement activation. In this study, we show that galactose incorporated in the IgG1–Fc enhances C1q binding, C4, C3 deposition, and complement-dependent cellular cytotoxicity in human erythrocytes and Raji cells. IgG1–Fc sialylation slightly enhanced binding of C1q, but had little effect on downstream complement activation. Using various mutations that decrease or increase hexamerization capacity of IgG1, we show that IgG1–Fc galactosylation has no intrinsic effect on C1q binding to IgG1, but enhances IgG1 hexamerization potential and, thereby, complement activation. These data suggest that the therapeutic potential of Abs can be amplified without introducing immunogenic mutations, by relatively simple glycoengineering. Key Points Fc galactosylation enhances complement activity of WT IgG1, but not hexameric IgG. Fc galactosylation improves hexamerization potential of IgG1.
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1545-1554
Fc Galactosylation Promotes Hexamerization of Human IgG1, Leading to Enhanced Classical Complement Activation
Human IgG contains one evolutionarily conserved N-linked glycan in its Fc region at position 297. This glycan is crucial for Fc-mediated functions, including its induction of the classical complement cascade. This is induced after target recognition through the IgG–Fab regions, allowing neighboring IgG–Fc tails to associate through Fc:Fc interaction, ultimately leading to hexamer formation. This hexamerization seems crucial for IgG to enable efficient interaction with the globular heads of the first complement component C1q and subsequent complement activation. In this study, we show that galactose incorporated in the IgG1–Fc enhances C1q binding, C4, C3 deposition, and complement-dependent cellular cytotoxicity in human erythrocytes and Raji cells. IgG1–Fc sialylation slightly enhanced binding of C1q, but had little effect on downstream complement activation. Using various mutations that decrease or increase hexamerization capacity of IgG1, we show that IgG1–Fc galactosylation has no intrinsic effect on C1q binding to IgG1, but enhances IgG1 hexamerization potential and, thereby, complement activation. These data suggest that the therapeutic potential of Abs can be amplified without introducing immunogenic mutations, by relatively simple glycoengineering. Key Points Fc galactosylation enhances complement activity of WT IgG1, but not hexameric IgG. Fc galactosylation improves hexamerization potential of IgG1.